Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)

Background: The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses ≤ 10 g/m2 show remissions when exposed to high-dose ifosfamide (HDI) (i.e., doses > 10 g/m2), which supports a dose-response relationship for this drug. Because of a la...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 1998-08, Vol.9 (8), p.871-876
Hauptverfasser:	Buesa, J. M., López-Pousa, A., Martín, J., Antón, A., García del Muro, J., Bellmunt, J., Arranz, F., Valentí, V., Escudero, P., Menéndez, D., Casado, A., Poveda, A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Agents, Alkylating - adverse effects Biological and medical sciences Chemotherapy Female Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage high-dose ifosfamide Humans Ifosfamide - administration & dosage Ifosfamide - adverse effects Infusions, Intravenous Male Medical sciences Middle Aged Pharmacology. Drug treatments Sarcoma - drug therapy Sarcoma - pathology Soft Tissue Neoplasms - drug therapy Soft Tissue Neoplasms - pathology soft tissue sarcomas Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!